Tolerance of high-dose coenzyme Q10 in ALS
Study Purpose:
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
Disease:
Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALSStudy Type:
Interventional TrialStudy Category:
Drug TrialStudy Status:
Not enrollingPhase:
Study Chair(s)/Principal Investigator(s):
Merit Cudkowicz, Massachusetts General Hospital
Clinicaltrials.gov ID (11 digit #):
Neals Affiliated?
YesCoordinating Center Contact Information
.(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address)